A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Latest Information Update: 10 Dec 2023
At a glance
- Drugs Pazopanib (Primary)
- Indications Adenocarcinoma; Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms PAZOTHYR
- 09 Sep 2021 Results published in the European Journal of Cancer
- 31 May 2020 Primary endpoint (Time to treatment failure (TTF)) has not been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology